United Therapeutics Corporation $UTHR Stake Raised by Strs Ohio

Strs Ohio increased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 63.1% in the 4th quarter, Holdings Channel reports. The fund owned 16,416 shares of the biotechnology company’s stock after purchasing an additional 6,354 shares during the period. Strs Ohio’s holdings in United Therapeutics were worth $7,999,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Darwin Global Management Ltd. acquired a new position in United Therapeutics in the 3rd quarter worth about $317,617,000. Baillie Gifford & Co. acquired a new position in United Therapeutics in the 4th quarter worth about $157,390,000. UBS Group AG increased its position in United Therapeutics by 45.3% in the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares during the last quarter. Soleus Capital Management L.P. increased its position in United Therapeutics by 35.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 209,794 shares of the biotechnology company’s stock worth $60,284,000 after purchasing an additional 54,400 shares during the last quarter. Finally, Legal & General Group Plc increased its position in United Therapeutics by 0.6% in the 3rd quarter. Legal & General Group Plc now owns 199,656 shares of the biotechnology company’s stock worth $83,698,000 after purchasing an additional 1,137 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Bank of America upped their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Wells Fargo & Company upped their target price on United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 31st. UBS Group upped their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Royal Bank Of Canada upped their target price on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Ten equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $601.50.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $581.22 on Tuesday. The firm has a market cap of $25.47 billion, a price-to-earnings ratio of 20.83, a P/E/G ratio of 1.62 and a beta of 0.60. The business’s 50-day simple moving average is $543.83 and its 200-day simple moving average is $498.27. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $607.89.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.19 EPS. As a group, equities research analysts forecast that United Therapeutics Corporation will post 27.97 earnings per share for the current year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Christopher Patusky sold 2,910 shares of the firm’s stock in a transaction that occurred on Friday, April 24th. The stock was sold at an average price of $569.00, for a total value of $1,655,790.00. Following the sale, the director owned 1,490 shares of the company’s stock, valued at $847,810. This trade represents a 66.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $572.61, for a total value of $5,726,100.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,808,586.36. This trade represents a 34.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 456,155 shares of company stock valued at $248,660,944 in the last 90 days. 10.30% of the stock is currently owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.